Do you visit every supplier on-site?

Not always — and we are honest about that. For suppliers with current FDA, MHRA, or EU notified body inspection coverage we rely on the regulator's inspection as primary evidence, supplemented by a documented capability call. For other suppliers we either conduct an on-site audit ourselves or commission a recognised third-party audit firm. The choice and the reasoning are recorded in the Supplier File.

How often is a supplier re-qualified?

Every 12 months on a rolling cadence — sooner if a material change occurs, such as regulatory action, ownership change, beneficial-owner change, financial distress, or a quality event affecting an in-scope product.

What happens if a supplier you've approved fails inspection later?

We suspend further orders until the gap is documented as resolved. Open orders are managed individually: raised pre-shipment inspection intensity, additional batch-release evidence, or — where the failure is material — escalation to project replacement using a substitute supplier from the qualified network.

Do you share supplier files with clients?

We share qualification status summaries with clients on request, and we can share the underlying documentation under NDA where the client's own QMS requires it for their ISO 13485 §7.4 purchasing-control evidence.

How do you screen for sanctions and reputational risk?

Beneficial-owner screening against OFAC, UK HMT, EU consolidated, and UN Security Council lists at qualification and at every re-qualification, plus continuous monitoring of regulator action lists, adverse-news feeds, and corporate-distress signals between formal reviews.

Can you qualify a new supplier we already work with?

Yes. We can run our full qualification process against a supplier you nominate. Either we add them to our network for ongoing supply, or we deliver the qualification as a standalone service with a written report you can place in your own QMS.

How long does a full supplier qualification take?

Typically 6–10 weeks end-to-end depending on whether an on-site audit is required, supplier responsiveness, and the complexity of the product portfolio in scope. Initial screening alone completes within 3–5 working days.

E-E-A-T Pillar

Supplier Verification Process — How We Qualify Every Medical Supplier

Every manufacturer in our medical equipment network passes a documented, evidence-based qualification programme before they fulfil a single client order. The same bar applies whether the supplier is a global OEM, a specialist contract manufacturer, or a regional distributor — because in healthcare procurement, supplier risk is always buyer risk.

Medical device quality auditor reviewing ISO 13485 supplier documentation on a tablet inside a cleanroom manufacturing facility — On-site supplier qualification audit — ISO 13485 evidence review inside a partner manufacturing facility.

Capabilities

What this service covers

Legal & Corporate Verification

Company registration, ownership, beneficial-owner screening, sanctions and PEP checks across OFAC, UK HMT, EU consolidated, and UN lists.

Manufacturing Capability

Site visit (where feasible), capacity confirmation, technology stack review, key-personnel interviews, sub-tier supplier mapping.

Quality Management System

ISO 13485 certificate verification with the certifying body, scope review against in-scope products, internal & external audit-finding review.

Regulatory Standing

Device registration status in origin and destination markets; inspection history with FDA, MHRA, EU notified bodies, NMPA, ANVISA, TGA.

Financial Stability

Financial-statement review, payment-behaviour analysis, credit-bureau data, ongoing solvency monitoring through public signals.

Post-Market Surveillance

Complaint history, recall record, FSCA history, vigilance reporting record, MAUDE/EUDAMED database checks.

Chapter 01

Why supplier verification matters in medical procurement

In medical equipment procurement, supplier risk is buyer risk. If a manufacturer's quality management system is non-compliant, the buying hospital inherits that non-compliance the moment the product enters its store. If a manufacturer is sitting under an FDA Warning Letter or an MHRA Field Safety Notice, the buyer's shipment can be detained at the border, quarantined on arrival, or pulled from clinical use weeks after installation. If a manufacturer fails financially mid-project, lead times collapse, spares evaporate, and warranty coverage becomes worthless.

Supplier verification is the discipline of pricing those risks in before they materialise — not after. It is the single highest-leverage control in any medical procurement programme, and it is the reason TRADER PARTNERS LTD runs a documented supplier qualification programme against every manufacturer, distributor, and channel partner in our global network.

The qualification is captured in a controlled Supplier File maintained against a defined evidence list, refreshed on a rolling 12-month cadence, and re-triggered immediately whenever a material change occurs — a regulatory action, an ownership change, a quality event, a beneficial-owner change, or a financial-distress signal.

Chapter 02

The Supplier File — what we capture and why

Every Supplier File contains a defined, non-negotiable set of documents and assessments. Where evidence is not directly supplied by the manufacturer we obtain it independently from public registries, regulator inspection databases, third-party audit firms, sanctions databases, and credit-bureau feeds. The file is owned by a named qualification lead inside TRADER PARTNERS LTD, version-controlled, and reviewable on request by client quality teams under NDA.

Corporate registration, beneficial-ownership structure, and ultimate-parent disclosure
Sanctions and politically-exposed-person screening against OFAC, UK HMT, EU consolidated, and UN Security Council lists
Manufacturing site addresses, declared capacity, key personnel, and critical sub-tier supplier mapping
ISO 13485 certificate (or equivalent QMS evidence), with scope verified against the in-scope product portfolio and certifying body confirmed directly
Regulatory registrations in origin and destination markets — CE / UKCA / FDA 510(k) or PMA / MHRA / NMPA / ANVISA / TGA as applicable
Inspection history with major regulators, including any Form 483, Warning Letter, Import Alert, or notified body non-conformance
Product-level certificates: Declaration of Conformity, CE certificate, FDA listing, product registration certificates
Insurance: product liability and general business cover with adequate limits and named-territory coverage
Financial statements, payment history, and credit-bureau data covering the most recent 24-month window
Complaint, recall, and field-safety corrective-action history — cross-checked against MAUDE, EUDAMED, and the regulator action lists
Reference checks with at least two existing distributor or buyer relationships of comparable scale

Chapter 03

The four-stage qualification workflow

Our qualification workflow runs in four sequential stages. No stage can be skipped, and no supplier moves to the next stage until the prior stage's evidence is documented and reviewed by the qualification lead. The workflow is deliberately slower than commercial pressure usually wants — and that is the point.

Stage 1 — Initial screening: filters out structurally unsuitable suppliers (no QMS, no regulatory standing, beneficial-owner sanctions exposure, fundamental capability mismatch). Typically completes in 3–5 working days.
Stage 2 — Documentary review: structured collection and review of the full evidence list above. Independent corroboration of certificates with certifying bodies. Typically 2–4 weeks.
Stage 3 — Site or surrogate audit: an on-site quality audit, or — where the manufacturer holds current FDA / MHRA / notified body inspection coverage — a documented desktop assessment leveraging the regulator's audit as primary evidence. Typically 2–6 weeks.
Stage 4 — Commercial and reputational review: financial standing, insurance adequacy, reference checks, news and litigation screening. Approval is recorded against documented acceptance criteria.

Chapter 04

On-site audits, desktop assessments, and third-party audit reliance

We do not pretend that every supplier can be audited in person, and we do not pretend that a desktop assessment is equivalent to a physical site visit. We make a documented, risk-based decision per supplier. Manufacturers under active FDA, MHRA, or EU notified body inspection coverage receive a desktop assessment that leverages the regulator's inspection as primary evidence — augmented by a documented capability call with the manufacturer's quality lead. Manufacturers without recent regulator inspection coverage receive either an on-site audit conducted by our quality team or a commissioned audit from a recognised third-party audit firm. The choice is documented in the Supplier File together with the reasoning.

This pragmatic but rigorous posture is what allows us to operate a genuinely global network — covering UK, EU, MENA, sub-Saharan Africa, and Asia-Pacific — without falling into either of the two common failure modes: pretending desktop checks are audits, or refusing to qualify any supplier we have not personally visited.

Chapter 05

Rolling re-qualification and continuous monitoring

Qualification is not a one-off event — it is a state that has to be actively maintained. Every supplier in the network is re-qualified on a rolling 12-month cadence, with the cadence shortened wherever a material change occurs. Between formal re-qualifications we run continuous monitoring against publicly available signals: FDA Warning Letter feeds, MHRA Field Safety Notices, EU Safety Gate, notified body suspension lists, sanctions list updates, credit-bureau alerts, adverse-news feeds, and corporate-registry change notifications.

When a monitoring signal fires we open an investigation immediately. The investigation determines whether the signal materially changes the supplier's qualification status. If it does, we either re-qualify on a compressed timeline or we suspend further orders pending resolution.

Chapter 06

When a supplier fails — our exit and remediation discipline

If a supplier fails qualification or re-qualification we suspend further orders until the gap is documented as resolved. For open orders we run a risk-managed completion: pre-shipment inspection intensity is raised, batch release is gated on additional evidence, and — where the failure is material to patient safety or to legal market access — we escalate to project replacement with the substitute supplier sourced from the qualified network.

We do not quietly continue to source from a failed supplier in the hope that the issue resolves before anyone notices. That discipline is occasionally commercially uncomfortable. It is always the right answer. The cost of a supplier event hitting a client — a regulatory hold, a recall, a clinical incident — is always greater than the cost of switching suppliers proactively, and the reputational cost compounds.

Chapter 07

How our process aligns with ISO 13485, EU MDR, and FDA 21 CFR 820.50

ISO 13485 §7.4 requires medical device organisations to evaluate and select suppliers based on their ability to supply product in accordance with requirements. Our qualification programme is built directly against that clause and against the equivalent EU MDR Article 14 distributor obligations and FDA 21 CFR 820.50 purchasing controls. The evidence list, audit cadence, and approval workflow mirror what an external auditor would expect to see in a compliant manufacturer's own purchasing-control file.

Client quality teams operating their own ISO 13485 system can therefore rely on our Supplier File evidence to support their own §7.4 evaluation — significantly reducing the documentary burden of qualifying us as a distributor in their QMS.

Chapter 08

What clients get — practical outputs of our verification process

Verification is not paperwork for its own sake. The qualification produces tangible artefacts that clients use directly in their own quality systems and project files:

Supplier qualification status summary — shareable, NDA-friendly, suitable for client QMS records
Evidence pack: certificates, regulatory listings, insurance evidence, audit summary
Risk register entry per supplier, with mitigations and monitoring triggers
Quarterly monitoring update on any supplier with active client orders
Immediate notification of any material change affecting an active project
Documented exit plan and substitute-supplier nomination for every critical product

UK Company No. 16575073

13 Ashbourne Parade, London W5 3QS

Supplier & product documentation verified per order

Buyer questions

Frequently Asked Questions

Related Services & Resources

Medical Procurement Hub

Our pillar resource covering every service we offer worldwide.

Medical Equipment Supplier

End-to-end medical equipment supply for hospitals and clinics.

Medical Device Distributor

International distribution for CE / FDA-cleared medical devices.

Healthcare Supply Chain Solutions

Supply-chain design, logistics, and ongoing replenishment.

Global Medical Sourcing

Multi-region sourcing across UK, EU, MENA, Asia, Africa.

Quality Assurance

Our ISO 13485-aligned QMS, inspections, and traceability.

Regulatory Compliance

CE, FDA, MHRA, UKCA — how we keep shipments compliant.

Knowledge Center

Procurement guides, sourcing playbooks, regulatory updates.

Contact TRADER PARTNERS LTD

Speak to the procurement team — response within one business day.

Request a Quote from TRADER PARTNERS LTD

UK-registered (Company No. 16575073). Worldwide sourcing, verified suppliers, full compliance documentation. Tell us what you need and our team will respond within one business day.

Request a Quote View All Services